Scientists studied the drug in combination with a common chemotherapy in the late-stage study, the drugmaker said Tuesday. The volunteers had triple-negative breast cancer, one of the most challenging forms of the disease to treat, which had spread or couldn’t be operated.
Truqap, a potential new cancer blockbuster for Astra, recently won clearance in the US and the European Union for other types of breast cancer.
The new study’s outcome is disappointing but may help advance understanding of certain pathways, said
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
